FDA grants marketing approval for neuromodulation device to reduce fibromyalgia symptoms

The FDA has granted De Novo authorization for NeuroMetrix to market its Quell neuromodulation device as an aid for reducing fibromyalgia symptoms in adults with high pain sensitivity, according to a company press release.
“There is an unmet need for effective and safe fibromyalgia treatments,” Shai N. Gozani, MD, PhD, CEO of NeuroMetrix, said in the release. “Receiving this De Novo authorization is a key milestone toward the company's goal of making Quell available as a prescription treatment option for people living with fibromyalgia.
“We believe physicians treating

The FDA has granted De Novo authorization for NeuroMetrix to market its Quell neuromodulation device as an aid for reducing fibromyalgia symptoms in adults with high pain sensitivity, according to a company press release.
“There is an unmet need for effective and safe fibromyalgia treatments,” Shai N. Gozani, MD, PhD, CEO of NeuroMetrix, said in the release. “Receiving this De Novo authorization is a key milestone toward the company’s goal of making Quell available as a prescription treatment option for people living with fibromyalgia.
“We believe physicians treating